PAPER Nimmrich V, Szabo R, Nyakas C, Granic I, Reymann KG, Schröder UH, Gross G, Schoemaker H, Wicke K, Möller A, Luiten P
PAPER Wu HY, Tomizawa K, Oda Y, Wei FY, Lu YF, Matsushita M, Li ST, Moriwaki A, Matsui H14627704
THERAPEUTICS Janssen Pfizer PF-05236812 Immunotherapy (passive) Amyloid-Related Starting in September 2010, Pfizer and Jannssen AIP conducted a double-blind Phase 1 trial with an open-label extension at centers in the United States and South Korea. The adaptive trial ...
Huddersfield, United Kingdom
Superior School of MedicineMexico
Rougemont, United States
GRANT Tuesday, September 30, 2014- 11:45 BrightFocus Foundation Variable October 14, 2014 BrightFocus Foundation Alzheimer's Disease Research Award ...
THERAPEUTICS AstraZeneca Immunotherapy (passive) Amyloid-Related In February 2014, AstraZeneca started a multicenter Phase 1 trial in the United States, which is to enroll 242 people with mild to moderate Alzheimer's disease. The study will evaluate single and ...
THERAPEUTICS Eli Lilly & Co. N3pG-Aβ Monoclonal Antibody Immunotherapy (passive) Amyloid-Related In May 2013, Lilly started a Phase 1 study in 100 people on the spectrum of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease ...
No filters selected